Abstract
Organ transplantations can lead to post-transplant lymphoproliferative disorders (PT-LPDs) as a result of immunosuppressive therapy. PT-LPDs clearly differ from non-Hodgkin’s lymphomas occurring in immunocompetent patients, in terms of clinical presentation, pathological findings and treatment response. Several studies have tried to establish some prognostic factors but the small number of patients hinders the analysis. We studied 61 patients from two transplant centers who developed a PT-LPD after kidney (34 patients), heart (19 patients), lung (4 patients) or liver (3 patients) transplantation. Treatment consisted of modification of the immunosuppressive regimen, chemotherapy and/or monoclonal antibody infusions. Analyzing potential prognostic factors, we found that factors predictive of failure to achieve a complete remission were, in univariate analysis, a performance status (PS) ≥2 and negativity of the tumor for the Epstein-Barr virus (EBV), and in multivariate analysis, only the PS. Factors predictive of lower survival were, in univariate analysis, a PS >2, number of sites > 1, primary central nervous system (CNS) location, T-cell phenotype, monoclonality of the tumor, tumor negativity for EBV and chemotherapy as a first treatment; in multivariate analysis. only PS and the number of sites were statistically significant. The International Prognostic Index (IPI) failed to identify a patient subgroup with a lower survival or treatment response, whereas a simple index using PS and number of sites clearly identified three different groups. The median survival has not yet been reached in the lowerrisk group, whereas it is 34 months in the intermediate-risk patients and 1 month in the high-risk group. Studies on larger cohorts of patients need to be performed to confirm these data.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Opelz G, Henderson R, for the Collaborative Transplant Study (1993) Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 342:1514–1516
Leblond V, Sutton L, Dorent R et al. (1995) Lymphoproliferative disorders after organ transplantation: a report of 24 cases in a single center. J Clin Oncol 13:961–968
Penn I (1990) Cancers complicating organ transplantation. N Engl J Med 323: 1767–1769
Leblond V, Davi F, Charlotte F, Dorent R, Bitker MO, Sutton L, Gandjbakhch I, Binet JL, Raphael M (1998) Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 16:1–9
Randhawa PS, Yousem SA, Paradis IL el. al (1989) The clinical spectrum, pathology, and clonal analysis of Epstein-Barr virus-associated lymphoproliferative disorders in heart-lung transplant recipients. Am J Clin Pathol 92:177–185
Armitage JM, Kormos RL, Stuart RS et al. (1991) Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 10:877–887
Nalesnik MA, Jaffe R, Starzl TE et al (1988) The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine Aprednisone immunosuppression. Am J Pathol 133:173–192
Hanto DW, Frizzera G, Galj-Peczalska et aL (1985) Epstein-Barr virus, immunodeficiency, and B-cell lymphoproliferation. Transplantation 39:461–472
Knowles DM, Cesarman E, Chadburn A et al. (1995) Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85:552–565
The international non-Hodgkin’s lymphoma prognostic factors project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994
Shipp MA (1994) Prognostic factors in aggressive non-Hodgkin lymphoma: who has “high-risk” disease? Blood 83:1165–1173
Fischer A, Blanche S, Le Bidois J et al. (1991) Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 324:1451–1456
Stephan JL, Le Deist F, Blanche S et al. (1992) Treatment of central nervous system B lymphoproliferative syndrome by local infusion of a B cell-specific monoclonal antibody. Transplantation 54:246–249
Durandy A, Emilie D, Peuchmaur M et al. (1994) Role of IL-6 in promoting growth of human EBV-induced B-cell tumors in severe combined immunodeficient mice. J Immunol 52:5361–5367
Milpied N, Vasseur B, Parquet N et al. (2000) Humanized anti-CD20 monoclonal antibody (rituximab) in B posttransplant lymphoproliferative disorders: a retrospective analysis on 32 patients. Ann Oncol 11 (Suppl 1): S 113–116
Harris NL, Ferry JA, Swerdelow SH (1997) Posttransplant lymphoproliferative disorders: summary of Society for Hemathopathology Workshop. Semin Diagn Pathol 14:8–14
Hsu SM, Raine L, Fanger H (1981) Use of avidin biotin peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabeled (PAP) procedures. J Histochem Cytochem 29:577–580
Cordell JL, Falini B, Erber WN (1984) Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphate anti alkaline phosphatase (APAAP complex). J Histochem Cytochem 32:219–229
Barletta JM, Kingma DW, Ling Y et al (1993) Rapid in situ hybridization for the diagnosis of latent Epstein-Barr virus infection. Mol Cell Probes 7:105–109
Kaplan AL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 54:457–481
Cox DR (1972) Regression model and Mfe tables. J R Stat Soc B 74:187–220
Grambsch PM, Therneau TM (1994) Proportional hazards tests and diagnostics based on weighted residual. Biometrika 81:515–526
Benkerrou M, Jais JP, Leblond V et al. (1998) Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 92:3137–3147
Penn I, Porat G (1995) Central nervous system in organ allograft recipients. Transplantation 59:240–244
Waller EK, Ziemianska M, Bangs CD et al. (1993) Characterization of posttransplant lymphomas that express T-cell-associated markers: immunophenotypes, molecular genetics, cytogenetics, and heterotransplantation in severe combined immunodeficient mice. Blood 82:247–261
Hanson MN, Morrison VA, Peterson BA et al. (1996) Posttransplant T-cell lymphoproliferative disorders: an aggressive, late complication of solid-organ transplantation. Blood 88:3626–3633
Morrison VA, Dunn DL, Manivel JC, Gfil-Peczalska KL Peterson BA (1997) Clinical characteristics of posttransplant lymphoproliferative disorders. Am J Med 97:14–24
Swinnen LJ Mullen GM, Carr TJ, Costanzo MR, Fisher RI (1995) Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 86:3333–3340
Garett TL Chadburn A, Barr ML et al. (1993) Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristineprednisone chemotherapy. Cancer 72:2782
Kingma DW, Weiss WB, Jaffe ES et al. (1996) Epstein-Barr virus latent membrane protein-1 oncogene deletions correlations with malignancy in Epstein-Barr associated lymphoproliferative disorders and malignant lymphomas. Blood 88:242
Murray PG, Swinnen LJ, Constandinou CM et al. (1996) Bcl-2 but not its Epstein-Barr virus-encoded homologue BHRFl, is commonly expressed in post-transplantation lymphoproliferative disorders. Blood 87:706
Horwitz SM, Ranheim EA, Morgan DS, Horning SJ (1999) A unified approach to posttransplant lymphoproliferative disorder (PTLD): improved outcome and analysis of prognostic factors (abstract). Blood 94 (Suppl 1):2295
Habermann TM, Ansell SM, Velosa JA et al. (1999) Posttransplant lymphoproliferative disorders (PTLD): long-term outcome and prognostic factors (abstract). Blood 94 (Suppl 1):2296
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Choquet, S. et al. (2002). Identification of Prognostic Factors in Post-Transplant Lymphoproliferative Disorders. In: Oertel, S.H., Riess, H. (eds) Immunosurveillance, Immunodeficiencies and Lymphoproliferations. Recent Results in Cancer Research, vol 159. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56352-2_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-56352-2_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62676-0
Online ISBN: 978-3-642-56352-2
eBook Packages: Springer Book Archive